

IN THE CLAIMS

This listing of the claims replaces all prior versions and listings of claims in the application:

1. - 101. (Canceled)

102. (Currently amended) A therapeutic bioconjugate that inhibits inflammatory cell adhesion consisting of:

[[~~(a)~~]] a hydrophilic polymer cross-linked to [[; and (b)]] a peptide comprising having the amino acid sequence Cys Asn Ala Phe Lys Ile Leu Val Val Ile Thr Asp Gly Glu Lys (SEQ ID NO:124); wherein the peptide of said therapeutic bioconjugate binds to a cell expressing an intercellular adhesion molecule (ICAM) and the hydrophilic polymer inhibits monocyte adhesion to said cell; and wherein the degree of inhibition of monocyte adhesion by said bioconjugate is at least five-times that of said peptide alone.

103.-104. (Canceled)

105. (Currently amended) A therapeutic bioconjugate that inhibits inflammatory cell adhesion consisting of:

[[~~(a)~~]] a polysaccharide cross-linked to [[; and (b)]] a peptide comprising having the amino acid sequence Cys Asn Ala Phe Lys Ile Leu Val Val Ile Thr Asp Gly Glu Lys (SEQ ID NO:124); wherein said therapeutic bioconjugate binds to a cell expressing an intercellular adhesion molecule and inhibits monocyte adhesion to said cell; and wherein the degree of inhibition of monocyte adhesion by said bioconjugate is at least five-times that of said peptide alone.

106. (Previously presented) The therapeutic bioconjugate of claim 105, wherein the polysaccharide is dextran.